Eva Richard

Dr. Eva Richard

Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM). Universidad Autónoma de Madrid.
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2009 in Human Mutation
Verified
Journal Article
Closed access
PDF file
EREva Richard
Eva Richard
AJAna Jorge-Finnigan
Ana Jorge-Finnigan
JGJudit Garcia-Villoria
Judit Garcia-Villoria
BMBegoña Merinero
Begoña Merinero
LDLourdes R. Desviat
Lourdes R. Desviat
María L. CouceMaría L. Couce
María L. Couce

1 February 2002 in Blood
Verified
Journal Article
Open access
FAFrancisco X. Arredondo-Vega
Francisco X. Arredondo-Vega
ISInes Santisteban
Ines Santisteban
EREva Richard
Eva Richard
PBPawan Bali
Pawan Bali
MKMajed Koleilat
Majed Koleilat
MHMichael S. Hershfield
Michael S. Hershfield
Four patients from 3 Saudi Arabian families had delayed onset of immune deficiency due to homozygosity for a novel intronic mutation, g.31701T>A, in the last splice acceptor site of the adenosine deaminase (ADA) gene. Aberrant splicing mutated the last 4 ADA amino acids and added a 43-residue “tail” that rendered the protein unstable. Mutant complementary DNA (cDNA) expressed inEscherichia coli yielded 1% of the ADA activity obtained with wild-type cDNA. The oldest patient, 16 years old at diagnosis, had greater residual immune function and less elevated erythrocyte deoxyadenosine nucleotides than his 4-year-old affected sister. His T cells and Epstein-Barr virus (EBV) B cell line had 75% of normal ADA activity and ADA protein of normal size. DNA from these cells and his whole blood possessed 2 mutant ADA alleles. Both carried g.31701T>A, but one had acquired a deletion of the 11 adjacent base pair, g.31702-12, which suppressed aberrant splicing and excised an unusual purine-rich tract from the wild-type intron 11/exon 12 junction. During ADA replacement therapy, ADA activity in T cells and abundance of the “second-site” revertant allele decreased markedly. This finding raises an important issue relevant to stem cell gene therapy.

1 March 2000 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
CPC Pérez-Cerdá
C Pérez-Cerdá
BMB Merinero
B Merinero
PRP Rodríguez-Pombo
P Rodríguez-Pombo
BPB Pérez
B Pérez
LDLr Desviat
Lr Desviat
MUM Ugarte
M Ugarte

30 October 2000 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
EREva Richard
Eva Richard
FAFrancisco X. Arredondo-Vega
Francisco X. Arredondo-Vega
ISInes Santisteban
Ines Santisteban
SKSusan J. Kelly
Susan J. Kelly
DPDhavalkumar D. Patel
Dhavalkumar D. Patel
MHMichael S. Hershfield
Michael S. Hershfield
Human, but not murine, adenosine deaminase (ADA) forms a complex with the cell membrane protein CD26/dipeptidyl peptidase IV. CD26-bound ADA has been postulated to regulate extracellular adenosine levels and to modulate the costimulatory function of CD26 on T lymphocytes. Absence of ADA–CD26 binding has been implicated in causing severe combined immunodeficiency due to ADA deficiency. Using human–mouse ADA hybrids and ADA point mutants, we have localized the amino acids critical for CD26 binding to the helical segment 126–143. Arg142 in human ADA and Gln142 in mouse ADA largely determine the capacity to bind CD26. Recombinant human ADA bearing the R142Q mutation had normal catalytic activity per molecule, but markedly impaired binding to a CD26+ ADA-deficient human T cell line. Reduced CD26 binding was also found with ADA from red cells and T cells of a healthy individual whose only expressed ADA has the R142Q mutation. Conversely, ADA with the E217K active site mutation, the only ADA expressed by a severely immunodeficient patient, showed normal CD26 binding. These findings argue that ADA binding to CD26 is not essential for immune function in humans.

1 July 2016 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
LGL. Gallego-Villar
L. Gallego-Villar
ARA. Rivera-Barahona
A. Rivera-Barahona
CCC. Cuevas-Martín
C. Cuevas-Martín
AGA. Guenzel
A. Guenzel
BPB. Pérez
B. Pérez
LDLourdes Desviat
Lourdes Desviat

8 August 2012 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
EREva Richard
Eva Richard
LDLourdes R. Desviat
Lourdes R. Desviat
MUMagdalena Ugarte
Magdalena Ugarte
BPBelén Pérez
Belén Pérez